The REMATCH trial: rationale, design, and end points

Rose, Eric A.; Moskowitz, Alan J.; Packer, Milton; Sollano, Josephine A.; Williams, Deborah; Tierney, Anita R.; Heitjan, Daniel F.; Meier, Paul; Ascheim, Deborah D.; Levitan, Ronald G; Weinberg, Alan; Stevenson, Lynne Warner; Shapiro, Peter A.; Lazar, Ronald M.; Watson, John T.; Goldstein, Daniel J.; Gelijns, Annetine C.

doi:10.1016/s0003-4975(99)00042-9

Cited by 330 publications

(75 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies have shown improvement in the liver function in patients with mild abnormalities in pre-implant liver tests, and no deterioration in those with normal baseline values, up to 6 mo [118,120] . However, preexisting or post-LVAD severe liver dysfunction strikingly influences patients' prognosis and endangers their survival [121] .…”

Section: Ventricular Assist Devicesmentioning

confidence: 99%

Hepato-cardiac disorders

Fouad¹,

Yehia²

2014

WJH

111

View full text Add to dashboard Cite

Understanding the mutual relationship between the liver and the heart is important for both hepatologists and cardiologists. Hepato�cardiac diseases can be classified into heart diseases affecting the liver, liver diseases affecting the heart, and conditions affecting the heart and the liver at the same time. �ifferential diagnoses of liver injury are extremely important in a cardiologist's clinical practice calling for collaboration between cardiologists and hepatologists due to the many other diseases that can affect the liver and mimic haemodynamic injury. Acute and chronic heart failure may lead to acute ischemic hepatitis or chronic conges� tive hepatopathy. Treatment in these cases should be directed to the primary heart disease. In patients with advanced liver disease, cirrhotic cardiomyopathy may develop including hemodynamic changes, diastolic and systolic dysfunctions, reduced cardiac performance and electrophysiological abnormalities. Cardiac evaluation is important for patients with liver diseases especially before and after liver transplantation. Liver transplanta� tion may lead to the improvement of all cardiac chang� es and the reversal of cirrhotic cardiomyopathy. There are systemic diseases that may affect both the liver and the heart concomitantly including congenital, metabolic and inflammatory diseases as well as alcoholism. This review highlights these hepatocardiac diseases

show abstract

Section: Ventricular Assist Devicesmentioning

confidence: 99%

Hepato-cardiac disorders

Fouad¹,

Yehia²

2014

WJH

111

View full text Add to dashboard Cite

show abstract

“…(79,(87)(88)(89) Whilst their use in ACHD is increasing, their success is mainly reported in a number of case reports with no large randomised trial available to date.…”

Section: Ventricular Assist Devicesmentioning

confidence: 99%

Management of advanced adult congenital heart disease

Bowater

2017

SAHJ

View full text Add to dashboard Cite

As surgical techniques continue to develop, for example as seen with the Norwood procedure for hypoplastic left heart syndrome, the number of patients with the most complex forms of CHD will continue to increase along with their associated long term complications. Our ability to manage these patients appropriately, therefore, must also develop alongside. The purpose of this review is to examine the management of these patients once they have developed advanced disease, including drug therapy, devices, transplant and end of life care. In particular, the unique problems posed by patients with a systemic right ventricle (RV) and univentricular circulations are discussed. DRUG THERAPY IN HEART FAILUREIn patients with complex congenital heart disease, either palliated or unoperated, the development of ventricular dysfunction and clinical heart failure are common and as discussed above, is a common cause of morbidity and mortality in this population.

show abstract

“…В дальнейшем по мере улучшения результатов клинического приме-нения ДМПК в 2002 г. FDA допустило клиническое использование НПП HeartMate XVE (Thoratec Corporation, Pleasanton, CA) в качестве DT [63]. Выбор пациентов для DT основывался на тех пациентах, которые имели множество противопоказаний к ТС, как обратимых, так и необратимых [64].…”

Section: имплантация насоса на постоянной основеunclassified

Durable Mechanical Circulation Support as an Alternative to Heart Transplantation

Gautier

Itkin

Шевченко

et al. 2016

RJTAO

View full text Add to dashboard Cite

1 ФГБУ «Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России, Москва, Российская Федерация 2 Московский физико-технический институт (государственный университет), кафедра физики живых систем, Москва, Российская Федерация 3 ГБОУ ВПО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России, кафедра кардиологии, Москва, Российская Федерация 4 ГБОУ ВПО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России, кафедра трансплантологии и искусственных органов, Москва, Российская Федерация В обзоре проведен сравнительный анализ лечения терминальной хронической сердечной недостаточнос-ти с помощью трансплантации сердца и длительной механической поддержки кровообращения. Показа-ны основные преимущества и ограничения трансплантации сердца и перспективы применения техноло-гии длительной механической поддержки кровообращения. Рассмотрены основные направления данной технологии, включая двухэтапную трансплантацию сердца (bridge to transplant -BTT), восстановления миокарда на фоне работы вспомогательного насоса (bridge to recovery -BTR) и имплантация вспомога-тельного насоса на постоянной основе (destination therapy -DT). In the review a comparative analysis of the treatment of end-stage chronic heart failure using heart transplantation and durable mechanical circulatory is conducted. It shows the main advantages and limitations of heart transplantation and the prospects of application of durable mechanical circulatory support technology. The main

show abstract

The REMATCH trial: rationale, design, and end points

Cited by 330 publications

References 20 publications

Hepato-cardiac disorders

Hepato-cardiac disorders

Management of advanced adult congenital heart disease

Durable Mechanical Circulation Support as an Alternative to Heart Transplantation

Contact Info

Product

Resources

About